Office of Compliance appoints policy director
Deborah Autor named CDER Office of Compliance Associate Director for Compliance Policy; she was Department of Justice lead counsel in the case that won FDA its right to collect "disgorgement fees" for GMP violations (1"The Pink Sheet" Oct. 23, 2000, p. 4). In her newly created position, Autor reports to Office of Compliance Acting Director David Horowitz...
You may also be interested in...
The Center for Drug Evaluation & Research Office of Compliance will be led by a director with experience in litigation and policy development rather than a background in the field offices.
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.
With a biosimilar Lucentis (ranibizumab) candidate recently filed and Soliris (eculizumab), Eylea (aflibercept) and Prolia (denosumab) candidates in Phase III development, Samsung Bioepis has moved into its new domestic headquarters to spearhead its journey to the next level.